PD-136,450: a CCK2 (gastrin) receptor antagonist with antisecretory, anxiolytic and antiulcer activity.
This study investigated the effects of PD-136,450 (PD), a highly selective ligand for the CCK2 receptor, on gastric acid and pancreatic secretions, gastric cytoprotection and anxious behaviour in the rat and rabbit. PD inhibited gastrin (but not dimaprit) stimulated acid secretion in anaesthetized and conscious rats (IC50 of 1 mg kg(-1) sc) and inhibited 14C-aminopyrine uptake in isolated gastric glands from rabbits. In addition, PD decreased dose-dependently gastric haemorrhagic lesions in rats treated orally with acidified ethanol. Both, the antisecretory effects on gastric acid secretion and the gastric cytoprotective effects were less potent compared with the proton pump inhibitor omeprazole. PD strongly increased pancreatic secretion, which was substantially inhibited by the CCK1 antagonist L-364,718 (but not by the CCK2 antagonist L-365,260). PD also showed significant anxiolytic activity as assessed by a black and white box two-compartment activity assay. Both, time spent in the dark compartment and latency for movement from the light to the dark compartment was increased by PD (similarly with 5 mg kg(-1) diazepam). In conclusion, PD inhibited gastrin-stimulated gastric acid secretion, decreased ethanol-induced damage to the gastric mucosa, stimulated pancreatic secretion (via CCK1 receptors) and displayed anxiolytic activity. Thus, PD may have utility as an adjunct therapy in peptic ulcer disease by countering the actions of gastrin and increasing acid neutralization and mucosal protection.
Bastaki
S M A
SM
Department of Pharmacology, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE. sbastaki@uaeu.ac.ae
Hasan
M Y
MY
Chandranath
S I
SI
Schmassmann
A
A
Garner
A
A
D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D005260:Female; D005744:Gastric Acid / Q000378:metabolism; D007211:Indoles / Q000494:pharmacology*; D008297:Male; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism; D010627:Phenethylamines / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D043887:Receptor, Cholecystokinin B / Q000037:antagonists & inhibitors*
D014151:Anti-Anxiety Agents; D000897:Anti-Ulcer Agents; D007211:Indoles; D010627:Phenethylamines; D043887:Receptor, Cholecystokinin B; C077645:PD 136450